Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Amit Vaid

Pulmonary Disease Falls Church, VA Medical Doctor

NPI 1558314658 CMS profile 116058

3300 Gallows Rd, Falls Church, VA 22042

Open in the dashboard

General payments

$9,927

362 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Amit Vaid of Falls Church, VA is reported in the CMS Open Payments database as having received $9,927 across 362 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 79th percentile of Pulmonary Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $337 16
2024 General $609 15
2023 General $4,187 85
2022 General $2,500 115
2021 General $246 14
2020 General $371 21
2019 General $1,676 96

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Amit Vaid
  • Pulmonary Disease median
  • Middle half of Pulmonary Disease
  • National median

In program year 2025, general payments to Amit Vaid were reported at $337. Among 8,914 Pulmonary Disease profiles paid that year, the median was $500 and the middle half received between $124 and $1,893.

Show as a table
Year Amit Vaid Pulmonary Disease median Middle half National median
2019 $1,676 $377 $109–$1,340 $163
2020 $371 $230 $56–$907 $114
2021 $246 $269 $68–$1,072 $132
2022 $2,500 $390 $100–$1,457 $149
2023 $4,187 $419 $114–$1,659 $160
2024 $609 $476 $123–$1,818 $164
2025 $337 $500 $124–$1,893 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Resmed Corp $2,360 3 payments
  2. GlaxoSmithKline, LLC. $866 62 payments
  3. Genentech USA, Inc. $818 37 payments
  4. AstraZeneca Pharmaceuticals LP $813 47 payments
  5. Genzyme Corporation $767 33 payments
  6. Boehringer Ingelheim Pharmaceuticals, Inc. $489 23 payments
  7. Amgen Inc. $368 15 payments
  8. Regeneron Healthcare Solutions, Inc. $363 13 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $300 13 payments
  10. Insmed, Inc. $267 14 payments
  11. Other $2,516 102 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $7,283 356 payments
  2. Consulting Fee $2,308 1 payment
  3. Education $271 4 payments
  4. Travel and Lodging $65 1 payment
Products named General payments · program years 2019–2025
  1. AIRSENSE $2,330 2 payments
  2. DUPIXENT Immunology $812 30 payments
  3. Xolair $715 32 payments
  4. Esbriet $405 18 payments
  5. TRELEGY ELLIPTA $370 30 payments
  6. TEZSPIRE $351 14 payments
  7. FASENRA $349 18 payments
  8. DUPIXENT Inflammation And Immunology $330 12 payments
  9. GLASSIA $316 14 payments
  10. NUCALA $314 19 payments
  11. Other $4,476 221 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 27 drugs

Part D claims

909

Median for Critical Care (Intensivists): 406

Drug cost

$333,365

Median for Critical Care (Intensivists): $197,260

Branded share of claims

75.2%

Median for Critical Care (Intensivists): 69%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 70 $82,317
Spiriva Respimat Tiotropium Bromide Brand 78 $55,416
Breo Ellipta Fluticasone/Vilanterol Brand 85 $40,349
Breztri Aerosphere Budesonide/Glycopyr/Formoterol Brand 52 $37,227
Eliquis Apixaban Brand 18 $26,907
Qvar Redihaler Beclomethasone Dipropionate Brand 43 $16,147
Arnuity Ellipta Fluticasone Furoate Brand 44 $10,604
Anoro Ellipta Umeclidinium Brm/Vilanterol Tr Brand 14 $8,697
Incruse Ellipta Umeclidinium Bromide Brand 12 $8,164
Spiriva Handihaler Tiotropium Bromide Brand 15 $7,628

The 10 drugs with the highest cost, of 27 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,531 Part D prescribers listed as Critical Care (Intensivists); they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 41 billing codes

Paid by Medicare

$215,729

Of which drugs: $16,394

Medicare patients

960

Average age 76

Services billed

3,713

505 women, 455 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 44%
COPD 39%
Heart failure 37%
Diabetes 35%
Atrial fibrillation 34%
Chronic kidney disease 31%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • SANOFI-AVENTIS U.S. LLC $95
  • Regeneron Healthcare Solutions, Inc. $31
  • GENZYME CORPORATION $27
$153 — —
TEZSPIRE
  • Amgen Inc. $57
$57 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $53
$53 — —
Prolastin-C Liquid
  • Grifols USA, LLC $30
$30 — —
NUCALA
  • GlaxoSmithKline, LLC. $27
$27 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

362 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pulmonary Disease in Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record